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In viral detection, the gold standard diagnostic methods employ virus isolation, antigen or antibody capture immunoassays, and molecular diagnostic tests. [1] [2] [3] [4] These are typically timeconsuming, expensive, and require a sophisticated clinical laboratory setup and technical expertise. Avoiding standard ELISA and RT-PCR based methods while achieving higher detection sensitivity with an easy, quick, and low-cost process would enable facile sensing for timely detection and control of pandemic outbreaks within surveillance and diagnostic networks;
this would be particularly valuable in low-resource or field-applicable environments. In viral therapeutics, prevention or treatment of viral infection typically relies on neutralizing antibodies (NAbs) against target epitopes on the viral surface. Production of NAbs can be triggered by vaccines or active viruses that invade hosts. However, NAbs may induce antibody-dependent enhancement of infection (e.g., dengue 5 ) or may not provide protection against new epidemics as a result of genetic drift (e.g., antigenic drift in influenza 6 ). A customizable molecular scaffold can be generated to fit any surface pattern to recognize the drifting virus and serve as a more reliable platform for viral therapeutics. This may be particularly useful when fighting many World
Health Organization priority "blueprint-viruses" such as Zika and HIV for which no approved or effective vaccines are available.
Infectious diseases, including viruses, bacteria, and microbial toxins, present a unique spatial pattern of antigens on their surfaces. [7] [8] [9] Existing weakly binding ligands (called "binders" herein)
that interact with these epitopes can be linked to a scaffold, but exhibit limited improvement on multivalent binding avidity when sporadically matching the average spacing of epitopes. [10] [11] [12] [13] [14] Herein, we demonstrate a unique strategy for potent viral detection and inhibition through a precise, spatial pattern-recognizing display of weak binders in two-dimensional (2D) space. This approach is particularly important for targeting disease-causing pathogens with complex patterns of surface antigens such as dengue virus (DENV). Previously used synthetic scaffolds (polymers, dendrimers, nanofibers, nanoparticles and lipid nanoemulsions) have been toxic and cannot address these patterns, because they are not as precise in ligand spacing or provide limited control over the scaffold shape and ligand valency [15] [16] [17] [18] 27 but will eventually be removed from the blood by the liver 27 and kidney 34, 35 and thus, could serve as therapeutic agents to inhibit and clear the virus from the patient.
In this study, we demonstrate our unique molecular platform strategy by directly targeting DENV virions through a star-shaped DNA nanoarchitecture. This architecture was strategically chosen and designed to multivalently arrange molecularly recognizable binders in a 2D manner to precisely mimic the complex spatial pattern of the DENV viral envelope proteins. Nanometerlevel precision matching of binders to protein epitope enables a potent interaction for sensing and inhibition.
Our viral sensing approach does not rely on nucleic acid amplification, sophisticated laboratory equipment, or other lengthy steps needed for viral isolation, ELISA, or RT-PCR based gold standard methods, yet provides much higher sensitivity (detection limit of 100 pfu/mL or 1,000 pfu/mL in human blood serum or plasma) through a much easier (simple mix-and-read), faster 
RESULTS AND DISCUSSION
Design and characterization of star-shaped DNA architecture. Dengue virus (DENV, Type-2 strain), an enveloped arbovirus from the Flaviviridae family, 39 was used herein to demonstrate our design strategy/concept. DENV was chosen because its envelope protein binding-domain III (ED3), a viral surface epitope, is organized into a complex icosahedral shape 40 with alternating clusters of three or five ED3 sites (Fig. 1a) ; this represents an extremely challenging pattern to target using previous inhibitor design strategies. By connecting the clusters of ED3 sites linearly, we determined that a star-shape, consisting of a interior pentagon connected to five exterior triangles, would provide an optimal multivalent scaffold (Fig. s1b) Based on the surface pattern of ED3 clusters, a star-shaped DNA nanostructure (DNA star) that contains five 4-arm junctions at the inner vertices is designed to match the pattern and spacing of ED3 clusters. Specifically, the DNA star is comprised of 21 oligonucleotides: five "scaffold" strands (S-1 to S-5) to form the internal edges, ten "edge" strands (E-1 to E-10) to connect internal and external edges, five "fix" strands (F-1 to F-5) to connect the external edges, and one "close" strand to cap the external edges of each triangle. (c) Characterization of the DNA star structure using native PAGE. On the left is the schematic of the DNA star structures characterized on the 4% non-denaturing PAGE. Lane-1: "Fix" strand; Lane-2: "Close" strand; Lane-3: "Scaffold" strand; Lane-4: "Edge" strand; Lane-5: P1; Lane-6: P1+P2; Lane-7: P1+P2+P3; Lane-8: P1+P2+P3+P4; Lane-9: P1+P2+P3+P4+P5 (full star); Lane-10: P1+P2+P3+P4+P5 (without "Close" strand). Based on the intensity quantifications of DNA species in each lane, yield of each full-size DNA complex formation (Lanes 6-10) is 100%, 98.2%, 81.2%, 86.3%, 88.1%, and 98.3%, respectively. (d) In the absence of viral target, single-stranded regions in S-1, S-2, S-3, S-4, and S-5 form stem loops. AFM image further confirms structural formation of DNA star in its "contracted" form. Scale bar indicates 50-nm.
The formation of the DNA star was first characterized by a non-denaturing polyacrylamide gel electrophoresis (PAGE) that showed the expected species that corresponded to the full DNA star complex (Lane-9 on the gel in Additionally, AFM may display the overall shape of DNA star but cannot fully resolve the details of the structure due to the limited resolution.
DNA star-based DENV sensing. A DNA star for viral detection and inhibition (below) of DENV (serotype 2, referred to as just DENV) was prepared by placing a ED3-binding aptamer (called "aptamer" herein) 41 at all ten vertices of the DNA star to form a star-aptamer complex that geometrically matches and targets ED3 clusters (Fig. 2a) . DENV was chosen since the aptamer is well characterized and available for this serotype. The aptamer is a weak binder to DENV surface with a K D (dissociation constant) of ~ 20 µM as determined by surface plasmon resonance (SPR) (Fig. s3) . A FAM (fluorophore) or BHQ-1 (quencher) molecule-carrying ssDNA was hybridized to each inner edge strand flanking the hairpin to turn the star-aptamer complex into a viral sensor. This sensor design was based on our hypothesis that in the absence of DENV, FAM and BHQ-1 molecules would be brought together by Watson-Crick base pairing in the stem, much like a molecular beacon. 42 Unlike a molecular beacon, which gives a fluorescent readout of target nucleic acid hybridization events, the hairpins would be pulled apart and In the presence of DENV, the binding interactions between aptamers and ED3 domains would pull FAM away from BHQ by fully converting hairpins to ssDNA, enabling a fluorescent readout. Sensing motifs were designed to be flanked by trivalent ED3 clusters in the presence of DENV. (b) A series of DENV concentrations are used to determine the limit of detection (LOD) of the star sensor in human serum (100 pfu/mL) and human plasma (1,000 pfu/mL). The detection sensitivity in plasma is lower than that in serum due to greater amount of clotting proteins, leading to solution turbidity and blocking of fluorescence signal. Error bars are mean ± s.d., n = 3.
The experimental data support our hypothesis, showing that the DNA star-aptamer sensor was able to directly detect DENV virions with high sensitivity, affording a limit of detection (LOD) of 100 pfu/mL and 1,000 pfu/mL, respectively in human blood serum and plasma (Fig. 2b) . days, or 10 days post infection. So, no gold standard method for DENV detection can achieve the same sensing capacity as that of our DNA star sensor in regard to the sensitivity, ease, quickness, and cost (see Fig. s4 and Table s2 for the detailed comparison). Additionally, our direct viral detection method can avoid the false positive sensing of IgG that is produced from the first DENV infection. In summary, the LOD of our sensor is well below the viral concentration (>10 5 pfu/mL, see Note s2) in patients on day [0] (or the onset of illness, when fever and a variety of symptoms start to occur and the virus begins to become very pathogenic). 44 Thus, detection before this date is highly beneficial to the patient and to the timely screening and control of pandemic outbreaks within surveillance and diagnostic networks. Given the ease, quickness, and low-cost of our sensing assay, our DNA star-based sensor would also be valuable in a low-resource or field-applicable environment.
DNA 9-loop based sensing (a control sensor).
We next prepared a control DNA platform that precisely orchestrated the valency and spacing of a greater number of ED3-binding aptamer ligands and FAM-BHQ-1 pairs in 1D space to test our hypothesis that the previously determined highly sensitive DENV detection provided by our DNA star design must rely on 2D aptamer-ED3 pattern matching. As illustrated in Fig. 3a , a 6-helix bundle DNA origami nanotube (DNA-NT)
carrying nine ssDNA loops (each 63-nt long on one side) and hinge points (on the other side) was designed using caDNAno (Fig. s5) . 45 Each ssDNA loop was flanked by a pair of FAM-BHQ molecules through DNA hybridization. Due to the stacking interactions (via π-π stacking)
between adjacent blunt-ended DNA segments, [46] [47] [48] we predicted that this bendable DNA-NT (called "9-loop" hereafter) would remain straight in the absence of binding targets and, thus, hold FAM and BHQ-1 molecules together in a quenching FRET. AFM imaging of the native 9-loop confirms this prediction by showing that the construct does remain straight with the expected length (Figs. 3a and s6) . AFM results also show that multiple 9-loop structures can join together as a result of blunt-ended DNA stacking. If the binding affinity/force resulting from the binding of 9-loop-aptamer complex to spherical-shaped DENV was comparable to that of star-aptamer complex to DENV, the linear 9-loop should bend its segments about the hinge points to maximally bind ED3 sites (Fig. 3a) . As a result, all the paired fluorophores and quenchers would become sufficiently separated to enable a fluorescence signal. We then decorated the 9-loop with eighteen ED3-binding aptamer ligands with various ligand spacing (7, 14, or 21 nm) in 1D space to test the ability of the 9-loop sensor to detect DENV (Fig. 3b) . Our experimental data revealed that none of these sensors were able to detect the presence of DENV (Fig. 3c) even at a very high viral load of 10 7 pfu/mL. Breaking the more stable Watson-Crick base pairing in the DNA star's five hairpins is much harder than disturbing blunt-ended DNA stacking in the 9-loop construct. Therefore, our results suggest that the 2D spatial pattern-recognition display was an essential "element" for turning a weak-binding ligand into a significantly stronger binder that could be used for both detection and viral inhibition by physically binding and wrapping the viral particles (below). For DENV, simply matching the spacing in 1D is insufficient for converting weakly-binding ligands into a strong multivalent binder.
We further verified the 9-loop nanostructure's sensing capabilities by using very strong biotinstreptavidin interactions to eliminate the possibility that the poor performance of the 9-loopaptamer sensor resulted from an unexpected design flaw. For this purpose, 9-loop-biotin complexes were made to test whether the structure could offer designed sensing capacity by targeting streptavidin-coated magnetic beads. The 9-loop-biotin complexes mimic the 9-loopaptamer sensors but relies on the much stronger (pM K D ) interaction of biotin to streptavidin to validate the design. 49 Since streptavidin spacing on magnetic beads is not known, various interbiotin distances were tested to inclusively survey the sensing capacity of the 9-loop sensor (Fig.   s7a ). If biotin spacing matched the streptavidin spacing, the strong biotin-streptavidin interactions would bend the 9-loop segments flanking the ssDNA loops, moving the quenchers and fluorophores apart, abrogating quenching and resulting in direct fluorescence detection (Fig. s7b) . Our data show that the fluorescence difference between quenched and unquenched states at different temperatures was significant; a biotin spacing of 7-nm flanking the loops afforded the best detection sensitivity (Figs. S8a/b). When biotin was spaced at a high density, at every 7-nm along the 9-loop, sensing capability was hindered due to steric hindrance from biotin crowding. In other words, a higher ligand density does not improve sensing capability even at the optimal inter-ligand spacing. This observation was further confirmed by fluorescence confocal microscopy image analysis (Fig. s8c) . We observed that the detection sensitivity increased as the temperature decreased, consistent with blunt-ended DNA stacking being more stable at lower temperatures, decreasing spontaneous movement of fluorophores away from quenchers. Additionally, we observed that fluorescence intensity generally decreased as the temperature increased, which agrees with previous studies. 50, 51 It should be noted that the above biotin-streptavidin interaction-mediated sensing result is not contradictory to our design concept but rather supports the notion that a precise, multivalent spatial pattern-recognition strategy should be able to turn any ligand, weak or strong, into an even stronger binder. Binding affinity assay of DENV to DNA-star, 9-loop, and monovalent aptamer. The binding avidities of the star-aptamer and the various 9-loop-aptamer complexes to DENV were assayed by SPR to determine whether the differentiated DENV detection ability of the DNA star and 9-loop sensors is due to their different binding avidities to the virus (Fig. s9) . Monovalent aptamer was used as a baseline control. Partial star-aptamer complexes (containing 1, 2, 3, or 4
triangles of the full star) serve as another set of controls to demonstrate the necessity of the full DNA star-aptamer complex to achieve high viral-binding affinity. The SPR results show that the binding of the DNA star-aptamer complex to DENV was stronger than all the partial staraptamer complexes (Fig. 4a) ; its binding was also > 100-fold stronger than the 9-loop-aptamer complexes or monovalent aptamer when normalized to the same concentration of aptamers (Fig. 4b) . Such observations confirm that matching both shape/pattern in 2D space and inter-ED3 spacing is critical for achieving high binding avidity (Figs. 4c and s10 ).
In vitro DENV inhibition. Encouraged by the sensing and SPR results, we tested the in vitro inhibition of DENV (plaque forming and EC 50 assays) using the DNA star-aptamer complex or monovalent aptamer (as a control) in human serum-containing solution optimized for a standard in vitro antiviral plaque assay. Briefly, the DENV serotype 2 viral particles were incubated with different concentrations of inhibitor (DNA star-aptamer complex or monovalent aptamer) in human serum and the remaining infectivity was determined by a plaque reduction assay (Fig.   5a ). Next, the dose-dependent inhibition of DENV was examined. The EC 50 value (half maximal effective concentration) of the DNA star-aptamer complex for DENV infection inhibition was ~ 2 nM, whereas the EC 50 value of the monovalent aptamer was ~ 15 µM (Fig. 5b ). These results demonstrate that the DNA star-aptamer multivalent inhibitor was ~ 7.5 × 10 3 -fold more effective than the monovalent aptamer for the in vitro inhibition of DENV infection in human serum. assays show that the DNA star-aptamer complex is ~ 7.5 × 10 3 -fold more effective than the monovalent aptamer at DENV infection inhibition in human blood serum. Error bars are mean ± s.e.m., n = 3. (c) Time-lapsed imaging assay of A594-labeled (top row) or DNA star sensorbound DENV (bottom row) shows viral entry or inhibition on HepG2 cells. In the case of A594-labeled viruses (red dots), both cell binding and internalization are shown over time. DNA star sensor-bound viruses (green dots) do not show the cell internalization. Cell nuclei (blue color) were stained with Hoechst. For each case, a white arrow is used to track the virion that was in the plane of focus throughout the confocal imaging assay from time 0-min. The same virion for each case was tracked in the supplemental movies (Movies s1 and s2). Scale bars indicate 5-μm. Note that other virions (shown in Fig. s11 and Movies s1 and s2) were also imaged when they came in or out of the focal plane during the time course.
We then carried out a time-lapsed, live confocal imaging assay to demonstrate that DENV virions can lose their cell internalization/infection ability after being bound by the DNA staraptamer complex. For the assay, HepG2 cells were mixed with the DNA star sensor-bound or Alexa 594-labeled virions in human serum-containing solution optimized for HepG2 cell culturing. HepG2 was chosen since it is a human cell line derived from the liver, an organ DENV can infect. The Alexa 594-labeled virion was used as a control to show positive viral cell entry/internalization. For each mixture, real-time imaging of the interactions between virions and HepG2 cells was performed. As shown in Fig. 5c, Fig. s11 and by Movie s1, after binding to DENV, the DNA star-aptamer complex is able to inhibit viral cell entry, and some of the DNA star-bound virions (green dots) also moved away from the HepG2 cells as time went on. On the contrary, the Alexa 594-labeled control virions (red dots) show the ability to adhere to the cell surface, and then pass through the cell membrane and approach the cell nucleus after internalization (Fig. 5c, Fig. s11 and Movie s2). In both conditions, HepG2 cell nuclei (blue color)
were stained with Hoechst. Confocal imaging has confirmed that our DNA star-aptamer complex has the capability to inhibit DENV at a single viral particle level by physical trapping and isolating DENV from host cells.
CONCLUSION AND OUTLOOK
Through targeting one of the most challenging exemplar platforms, the DENV flavivirus, we have demonstrated the unique concept of integrating a structurally defined DNA nanoarchitecture with precise, multivalent spatial pattern-recognition properties for direct, highlysensitive, easy, and rapid viral detection. Our sensor has clearly shown superiority over gold standard DENV detection methods and has promising use in field-applicable or low-resource environments. As is standard with viral infection screening, secondary confirmation of infection by some of the standard methods (e.g., viral isolation or nucleic acid sensing) should still be employed after the initial precautionary screening in order to make a full documentation and evaluation of an epidemic outbreak. Moreover, other monovalent aptamer combinations have been used as antiviral agents for human viruses. 52 Thus, our synthetic DNA star-aptamer complex has the potential to serve as a highly potent anti-DENV inhibitor in the treatment of infected individuals. As binders specific to other pathogenic domains can be evolved or synthesized, our strategy could be widely applicable by following a general DNA nanoplatform design principle (illustrated in Fig. 6 ) as various DNA 2D/3D structures can be designed and synthesized on-demand to mimic simpler surface epitope patterns of pathogenic viruses, bacteria, and microbial toxins.
Although DNA nanostructures have shown certain stability in vivo, 27, 35 the DNA star's component strands may be chemically modified (e.g., through methylation) to further improve its stability when preparing in vivo antiviral assays. In summary, the reported design strategy, by providing a unique perspective on the precise spatial pattern-recognition of pathogenic epitopes, holds promise for broad and effective applications.
